BALTIMORE, Nov. 5, 2013 /PRNewswire/-- Alba Therapeutics Corporation today announced the appointment of Wendy Perrow as its Chief Executive Officer (CEO). Her responsibilities include managing the Company's business, clinical, financial, licensing, and corporate development efforts. Ms. Perrow previously served as President and COO and she has been a member of Alba's executive management team since 2008.
Under her leadership, Alba Therapeutics established a collaborative funding agreement on February 9, 2011 with Cephalon Pharmaceuticals (now Teva Pharmaceuticals) and has taken a leading role in advancing multiple clinical studies in Celiac Disease. The company has conducted seven clinical trials in subjects with Celiac Disease and is currently conducting a large Phase IIb trial with the lead compound Larazotide Acetate.
"Ms. Perrow brings a wealth of global experience and leadership with a proven track record of success in both biotech and pharmaceutical companies," said Bruce Peacock Co-Chairman of Alba. "Wendy is a key member of our leadership team, driving deal making as well as clinical and financial strategy and her experience in leading successful research and development and commercial infrastructures has been invaluable to Alba."
Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with rare diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global and U.S. marketing for Anti-Hypertensives, Vaccines, Cholesterol, and GI. At Merck, she held positions in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson
|SOURCE Alba Therapeutics Corporation|
Copyright©2012 PR Newswire.
All rights reserved